Supply chain risk management strategies in normal and abnormal times: policymakers' role in reducing generic medicine shortages

被引:25
作者
Ahlqvist, Victoria [1 ]
Dube, Nonhlanhla [2 ]
Jahre, Marianne [3 ]
Lee, Jin Soo [4 ]
Melaku, Tsegaye [5 ]
Moe, Andreas Farstad [3 ]
Olivier, Max [6 ]
Selviaridis, Kostas [7 ]
Viana, Joe [3 ]
Aardal, Christine [8 ]
机构
[1] Lund Univ, Dept Ind Management & Logist, Lund, Sweden
[2] Univ Lancaster, Dept Management Sci, Lancaster, England
[3] BI Norwegian Business Sch, Dept Accounting & Operat Management, Oslo, Norway
[4] World Food Programme Kenya, Reg Bureaux, Nairobi, Kenya
[5] Jimma Univ, Inst Hlth, Jimma, Ethiopia
[6] Erasmus Univ, Dept Technol & Operat Management, Rotterdam, Netherlands
[7] Lancaster Univ Management Sch, Dept Management Sci, Lancaster, England
[8] Norwegian Inst Publ Hlth, Antibiot Resistance & Infect Prevent, Oslo, Norway
关键词
Medicine supply chain; Medicine shortages; Supply chain risk management; COVID-19; Paracetamol; Policymakers; HEALTH-CARE; RESILIENCE; DISRUPTION; FRAMEWORK; MODEL;
D O I
10.1108/IJPDLM-12-2021-0511
中图分类号
C93 [管理学];
学科分类号
12 ; 1201 ; 1202 ; 120202 ;
摘要
Purpose This paper links supply chain risk management to medicine supply chains to explore the role of policymakers in employing supply chain risk management strategies (SCRMS) to reduce generic medicine shortages. Design/methodology/approach Using secondary data supplemented with primary data, the authors map and compare seven countries' SCRMS for handling shortage risks in their paracetamol supply chains before and during the first two waves of the COVID-19 pandemic. Findings Consistent with recent research, the study finds that policymakers had implemented few SCRMS specifically for responding to disruptions caused by COVID-19. However, shortages were largely avoided since multiple strategies for coping with business-as-usual disruptions had been implemented prior to the pandemic. The authors did find that SCRMS implemented during COVID-19 were not always aligned with those implemented pre-pandemic. The authors also found that policymakers played both direct and indirect roles. Research limitations/implications Combining longitudinal secondary data with interviews sheds light on how, regardless of the level of preparedness during normal times, SCRMS can be leveraged to avert shortages in abnormal times. However, the problem is highly complex, which warrants further research. Practical implications Supply chain professionals and policymakers in the healthcare sector can use the findings when developing preparedness and response plans. Social implications The insights developed can help policymakers improve the availability of high-volume generic medicines in (ab)normal times. Originality/value The authors contribute to prior SCRM research in two ways. First, the authors operationalize SCRMS in the medicine supply chain context in (ab)normal times, thereby opening avenues for future research on SCRM in this context. Second, the authors develop insights on the role policymakers play and how they directly implement and indirectly influence the adoption of SCRMS. Based on the study findings, the authors develop a framework that captures the diverse roles of policymakers in SCRM.
引用
收藏
页码:206 / 230
页数:25
相关论文
共 108 条
[1]  
AESGP, 2020, SHORT MED PROD CIT E
[2]   Supply Chain Risk Governance: Towards a Conceptual Multi-Level Framework [J].
Ahlqvist, Victoria ;
Norrman, Andreas ;
Jahre, Marianne .
OPERATIONS AND SUPPLY CHAIN MANAGEMENT-AN INTERNATIONAL JOURNAL, 2020, 13 (04) :382-395
[3]  
[Anonymous], 2019, Drug Shortages: Root Causes and Potential Solutions
[4]  
[Anonymous], 2022, The Telegraph
[5]  
[Anonymous], 2021, PHARM IND FIG
[6]   Supply chain transparency and the availability of essential medicines [J].
Ardal, Christine ;
Baraldi, Enrico ;
Beyer, Peter ;
Lacotte, Yohann ;
Larsson, D. G. Joakim ;
Ploy, Marie-Cecile ;
Rottingen, John -Arne ;
Smith, Ingrid .
BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2021, 99 (04) :319-320
[7]   Short and long term impacts of COVID-19 on the pharmaceutical sector [J].
Ayati, Nayyereh ;
Saiyarsarai, Parisa ;
Nikfar, Shekoufeh .
DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 28 (02) :799-805
[8]   Managing pharmaceutical shortages: an overview and classification of policy responses in Europe and the USA [J].
Beck, Matthias ;
Buckley, Joan ;
O'Reilly, Seamus .
INTERNATIONAL REVIEW OF ADMINISTRATIVE SCIENCES, 2020, 86 (04) :622-640
[9]   Internet of Things - the future of managing supply chain risks [J].
Birkel, Hendrik Sebastian ;
Hartmann, Evi .
SUPPLY CHAIN MANAGEMENT-AN INTERNATIONAL JOURNAL, 2020, 25 (05) :535-548
[10]  
Blix H.S., 2021, TIDSKRIFTER NORSKE L, V4